CG
MLTX icon

Cutler Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cutler Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$8K Buy
2,500
+1,500
+150% +$81.4K ﹤0.01% 1381
2023
Q4 		$2K Sell
1,000
-1,200
-55% -$61.8K ﹤0.01% 3135
2023
Q3 		$8K Buy
+2,200
New +$121K ﹤0.01% 2604

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cutler Group's MLTX Position: Q1 2024 in Review

Cutler Group increased its MoonLake Immunotherapeutics (MLTX) stake by 127% in Q1 2024, buying an estimated $75.9K and bringing the position to 2,500 shares worth $125K. The position accounts for 0.04% of the portfolio, ranked #393.

Cutler Group first reported a position in MLTX in Q3 2023 and has held it in 3 quarters since. The position peaked at $136K in Q3 2023. 114 funds tracked by Wall St. Rank hold MLTX as of Q1 2024.

  • Cutler Group held 2,500 shares of MoonLake Immunotherapeutics worth $125K as of Q1 2024.
  • Cutler Group bought 1,400 MoonLake Immunotherapeutics shares in Q1 2024, an estimated $75.9K.
  • MoonLake Immunotherapeutics made up 0.04% of Cutler Group's portfolio in Q1 2024, its #393 holding.
  • Cutler Group first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 3 quarters since.
  • Cutler Group's MoonLake Immunotherapeutics position peaked at $136K in Q3 2023.
  • 114 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.